Centocor history

In the case of the ovarian cancer test that Centocor sold to Abbott, for example, Wall learned in 1981 that researchers at the Dana-Farber Cancer Institute in Boston had isolated antibodies that could detect ovarian cancer cells.

HS-PP: Centocor, Centocor Oncogene Research Partners LP, 9 June 1984.

For more on the development of recombinant insulin see Hall (1987 Hall, S. 1987.

The Wall Street Journal, February 20 [Google Scholar]); Fisher (1992 Fisher, L. M. 1992.

In January 1993 Centocor announced that it had halted its crucial clinical trial on Centoxin and had also ceased selling the drug in Europe, where the drug had been approved for some applications.

In June 1994 the FDA recommended ReoPro for approval.

In mid-1995 Centocor's major product initiatives included: ReoPro; CenTNF, a therapeutic product designed to treat rheumatoid arthritis and inflammatory bowel diseases; and Panorex, a cancer-fighting drug.

The drug, which would be marketed by Lilly, was expected to generate annual sales of $250 million by 1997.

19 and 25). Stanley Cohen and Herbert Boyer faced similar hostility to the commercialisation and patenting of their technology and founding of Genentech (see Smith Hughes, 2001 Smith Huges, S. 2001.

See for example the case of CellPro which became bankrupt after failing to win a patent dispute as described in Bar-Shalom and Cook-Deegan (2002 Bar-Shalom, A. and Cook-Deegan, R. 2002.

American Chemical Society: Modern Drug Discovery, [Google Scholar]); Farrell, Barnathan, and Weisman (2003).

Nature Biotechnology, Supplement to 19, : BE21–BE22. [Crossref] , [Google Scholar]); for more on Amgen's development and marketing of Epogen see Goozner (2004 Goozner, M. 2004.

Interview with J.P. Garnier by Ted Everson (12 July 2006).